James E Signorovitch

Summary

Affiliation: Analysis Group
Country: USA

Publications

  1. doi request reprint Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis
    James Signorovitch
    Analysis Group, Inc, Boston, MA 02199, USA Electronic address
    Cancer Treat Rev 40:285-92. 2014
  2. pmc Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs
    J E Signorovitch
    Health Economics and Outcomes Research, Analysis Group, Inc, Boston, MA 02199, USA
    Diabetes Obes Metab 15:335-41. 2013
  3. doi request reprint Persistence with nebivolol in the treatment of hypertension: a retrospective claims analysis
    James E Signorovitch
    Analysis Group, Inc, Boston, MA, USA
    Curr Med Res Opin 28:591-9. 2012
  4. doi request reprint Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research
    James E Signorovitch
    Analysis Group, Inc, Boston, MA 02199, USA
    Value Health 15:940-7. 2012
  5. doi request reprint Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorde
    James Signorovitch
    Analysis Group, Inc, Boston, MA, United States
    Pharmacoepidemiol Drug Saf 21:130-7. 2012
  6. doi request reprint Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension
    J Signorovitch
    Analysis Group Inc, Boston, MA 02199, USA
    Curr Med Res Opin 26:849-60. 2010
  7. doi request reprint Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials
    James E Signorovitch
    Analysis Group Inc, Boston, MA 02199, USA
    Clin Drug Investig 31:665-74. 2011
  8. doi request reprint Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials
    James E Signorovitch
    Analysis Group, Boston, MA 02199, USA
    Curr Med Res Opin 27:1263-71. 2011
  9. doi request reprint Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin
    James E Signorovitch
    Analysis Group, Inc, Huntington Avenue, Tenth Floor, Boston, MA 02199, USA
    Curr Med Res Opin 26:355-63. 2010
  10. doi request reprint Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors
    James Signorovitch
    Analysis Group, Inc, Boston, MA, USA
    Curr Med Res Opin 27:1089-96. 2011

Detail Information

Publications16

  1. doi request reprint Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis
    James Signorovitch
    Analysis Group, Inc, Boston, MA 02199, USA Electronic address
    Cancer Treat Rev 40:285-92. 2014
    ..The objective of this study was to indirectly compare these therapies using evidence from randomized trials versus imatinib, the current standard of care...
  2. pmc Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs
    J E Signorovitch
    Health Economics and Outcomes Research, Analysis Group, Inc, Boston, MA 02199, USA
    Diabetes Obes Metab 15:335-41. 2013
    ..To assess associations between hypoglycaemia and risk of accidents resulting in hospital visits among people with type 2 diabetes receiving antidiabetes drugs without insulin...
  3. doi request reprint Persistence with nebivolol in the treatment of hypertension: a retrospective claims analysis
    James E Signorovitch
    Analysis Group, Inc, Boston, MA, USA
    Curr Med Res Opin 28:591-9. 2012
    ..Examine drug persistence by evaluating the hazard of discontinuation and of switching to different antihypertensive drugs in patients initiating treatment with a recently approved β-blocker, nebivolol, versus other β-blockers...
  4. doi request reprint Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research
    James E Signorovitch
    Analysis Group, Inc, Boston, MA 02199, USA
    Value Health 15:940-7. 2012
    ..The objective of this study was to demonstrate how incorporating individual patient data (IPD) from trials of one treatment into indirect comparisons can address several limitations that arise in analyses based only on aggregate data...
  5. doi request reprint Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorde
    James Signorovitch
    Analysis Group, Inc, Boston, MA, United States
    Pharmacoepidemiol Drug Saf 21:130-7. 2012
    ....
  6. doi request reprint Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension
    J Signorovitch
    Analysis Group Inc, Boston, MA 02199, USA
    Curr Med Res Opin 26:849-60. 2010
    ..The approaching availability of lower-cost generic angiotensin receptor blockers (ARBs) may affect formulary policies for patients maintained on the ARB valsartan...
  7. doi request reprint Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials
    James E Signorovitch
    Analysis Group Inc, Boston, MA 02199, USA
    Clin Drug Investig 31:665-74. 2011
    ..The aim of this study was to compare 12-week glycaemic control with vildagliptin 50 mg twice daily versus sitagliptin 50 or 100 mg once daily in Japanese patients with type 2 diabetes...
  8. doi request reprint Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials
    James E Signorovitch
    Analysis Group, Boston, MA 02199, USA
    Curr Med Res Opin 27:1263-71. 2011
    ..The purpose of this study was to indirectly compare rates of major molecular response (MMR), progression-free survival (PFS) and overall survival by month 12 with nilotinib and dasatinib treatment of newly diagnosed CML-CP...
  9. doi request reprint Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin
    James E Signorovitch
    Analysis Group, Inc, Huntington Avenue, Tenth Floor, Boston, MA 02199, USA
    Curr Med Res Opin 26:355-63. 2010
    ..Current CAP treatment guidelines do not differentiate between outpatient treatment with levofloxacin and moxifloxacin...
  10. doi request reprint Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors
    James Signorovitch
    Analysis Group, Inc, Boston, MA, USA
    Curr Med Res Opin 27:1089-96. 2011
    ....
  11. doi request reprint Increased olanzapine discontinuation and health care resource utilization following a Medicaid policy change
    James Signorovitch
    Analysis Group, Inc, 111 Huntington Ave, Boston, MA 02199, USA
    J Clin Psychiatry 72:787-94. 2011
    ..The announced policy change, effective on July 11, 2005, but rescinded on September 9, 2005, reclassified olanzapine as nonpreferred and gave physicians 60 days to change antipsychotics for current users...
  12. doi request reprint Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept
    James E Signorovitch
    Analysis Group Inc, Boston, Massachusetts, USA
    Pharmacoeconomics 28:935-45. 2010
    ....
  13. doi request reprint A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care
    Gregory S Sawicki
    Division of Respiratory Diseases, Children s Hospital Boston, Harvard Medical School, Boston, Massachusetts
    Pediatr Pulmonol 48:954-61. 2013
    ..Pulmonary exacerbations (PEx) lead to substantial morbidity in cystic fibrosis (CF), and guidelines recommend chronic medication including dornase alfa and inhaled tobramycin. However PEx risk and medication use vary across patients...
  14. doi request reprint Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction
    Jens Jakob Thune
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Eur J Heart Fail 13:148-53. 2011
    ..IMS: Recurrent myocardial infarction (MI) is common after a first MI and is associated with increased morbidity and mortality. Predictors and prognosis of a recurrent MI with contemporary management are not well known...
  15. doi request reprint Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial
    George V Moukarbel
    Division of Cardiovascular Diseases, Department of Internal Medicine, Brigham and Women s Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
    Eur Heart J 30:2226-32. 2009
    ..Risk factors for GI bleeding in post- myocardial infarction (MI) patients have not been well defined. We sought to identify risk factors for GI bleeding in patients following MI...
  16. doi request reprint Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution
    Gregory S Sawicki
    Division of Respiratory Diseases, Children s Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA
    Pediatr Pulmonol 47:44-52. 2012
    ..This study aimed to assess the association between use of tobramycin inhaled solution and mortality in patients with CF and chronic Pseudomonas aeruginosa (PA) infection...